Skip to main content
QTRX
NASDAQ Life Sciences

CEO Exits Immediately; Commercial Chief Takes Over as Interim

Tom Rudovsky · Reported by BusinessWire
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.86
Mkt Cap
$135.788M
52W Low
$2.15
52W High
$8.77
52W Position info
33% above low
Off High info
67% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

QTRX sits 33% above its 52-week low of $2.15.

Summary

Everett Cunningham is out as President, CEO and board member effective immediately, leaving to take a role elsewhere in healthcare, and the company said the departure is not related to any disagreements with the Company on any matter relating to its operations, policies, practices (financial or otherwise) or any issues regarding financial disclosures, accounting, or legal matters. The board named Chief Commercial Officer Jim Gute interim CEO, engaged a nationally recognized executive search firm to assist with the CEO search process and will consider both internal and external candidates, and Cunningham stays available through December 11, 2026. Gute will be paid a $750,000 annualized salary while serving in the role. The abrupt exit comes just nine days after Q3 results showed $35M in revenue and a $21.6M net loss, and the company reaffirmed the 2026 outlook it gave on November 9. Gute only joined as CCO in August 2026, so the bench depth behind him is thin. The reaffirmed guidance limits the damage, but a surprise CEO departure at a company this size is a governance overhang until a permanent leader is named.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — Interim CEO Jim Gute will be paid a $750,000 annualized salary while serving in the role.

    • Cunningham's departure is not related to any disagreements with the Company on any matter relating to its operations, policies, practices (financial or otherwise) or any issues regarding financial disclosures, accounting, or legal matters.
    • The Board has engaged a nationally recognized executive search firm to assist with the CEO search process and will consider both internal and external candidates.

At the time of this announcement, QTRX was trading at $2.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $135.8M. The 52-week trading range was $2.15 to $8.77. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

QTRX - Latest Insights

QTRX
Nov 09, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.90
Real-time Price: $2.21 info
Change: -$0.686 (-24%) info
Market Cap: $108.256M info
QTRX
Oct 07, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.44
Real-time Price: $2.21 info
Change: -$1.23 (-36%) info
Market Cap: $108.256M info
QTRX
Aug 10, 2026, 8:34 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.58
Real-time Price: $2.21 info
Change: -$0.371 (-14%) info
Market Cap: $108.256M info
QTRX
Aug 10, 2026, 8:12 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $2.71
Real-time Price: $2.21 info
Change: -$0.501 (-18%) info
Market Cap: $108.256M info
QTRX
Aug 10, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.68
Real-time Price: $2.21 info
Change: -$0.471 (-18%) info
Market Cap: $108.256M info